. "0"^^ . . "6"^^ . ""@en . "1"^^ . . "P\u0159edm\u011Btem navrhovan\u00E9ho projektu je studium mo\u017Enost\u00ED vyu\u017E\u00EDt bun\u011Bk s um\u011Ble vnesen\u00FDm genem pro IL-2 a IL-6 a vyu\u017E\u00EDt rekombinantn\u00EDch IL-2 a IL-6 polypeptid\u016F pro l\u00E9\u010Den\u00ED zbytkov\u00E9 choroby n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED na t\u0159ech experiment\u00E1ln\u00EDch modelech: 1) Na modelu my\u0161\u00ED myeloidn\u00ED leukemie (bu\u0148ky linie C1498 rostouc\u00ED na syngenn\u00EDch C57B1/6 nebo na semisyngenn\u00EDch F1 - B6 x Balb/c p\u0159\u00EDjemc\u00EDch). 2) Na modelu my\u0161\u00EDho plasmocytomu (bu\u0148ky linie X63-Ag8.653 rostouc\u00ED na syngenn\u00EDch Balb/c p\u0159\u00EDjemc\u00EDch). 3) Na modelu my\u0161\u00EDho sarkomu (bu\u0148ky sarkomu indukovan\u00E9ho MSV Harvey rostouc\u00ED na syngenn\u00EDch 810 p\u0159\u00EDjemc\u00EDch). Zbytkov\u00E1 chorobba bude l\u00E9\u010Dena po chemoterapii cytostatiky."@cs . . . "L\u00E9\u010Dba zbytkov\u00E9 choroby pomoc\u00ED IL-2 a IL- 6 v modelov\u00FDch syst\u00E9mech myeloidn\u00ED leukemie, plasmocytomu a retrovirov\u00FDch sarkom\u016F"@cs . . . . "620"^^ . "IL-2 and IL-6 Therapy of Residual Disease in Preclinical Models of Myeloid Leukaemia, Plasmacytomas and Retrovirus-Induced Sarcomas"@en . "0"^^ . "620"^^ . "6"^^ .